Related Experiment Video
Updated: May 18, 2026
10:29
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
Published on: March 24, 2017
Bridging the gap between a TB drug and its target
1Department of Microbiology and Immunology, Otago School of Medical Sciences, University of Otago, Post Office Box 56, Dunedin 9054, New Zealand. gregory.cook@otago.ac.nz
Science Translational Medicine
|September 8, 2012
Summary
A new tuberculosis drug was crystallized with its target, creating a foundation for designing better drugs to combat this infectious disease.
Area of Science:
- Drug discovery and development
- Structural biology
- Tuberculosis research
Background:
- Tuberculosis (TB) remains a significant global health challenge.
- Development of novel anti-TB drugs is crucial to overcome drug resistance.
- Structure-based drug design offers a rational approach to optimize drug candidates.
Purpose of the Study:
- To present the crystal structure of a novel TB drug in complex with its mycobacterial target.
- To establish a platform for structure-based design of improved anti-TB agents.
Main Methods:
- Cocrystallization of the novel TB drug with its mycobacterial target.
- X-ray crystallography to determine the 3D structure of the complex.
- Structure analysis to identify key interactions and potential modification sites.
Main Results:
- The crystal structure of the TB drug-mycobacterial target complex was successfully determined.
- The structure reveals critical binding interactions, providing insights into the drug's mechanism of action.
- The obtained structure serves as a template for rational drug design.
Conclusions:
- The cocrystallized structure provides a valuable platform for structure-based design of next-generation TB drugs.
- This approach is expected to accelerate the development of more effective treatments for tuberculosis.
- Further optimization based on this structural information holds promise for improving TB drug development pipelines.
Related Concept Videos
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:28Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:30Prodrugs
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
01:16Drug Biotransformation: Overview
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...